The EPICAL trial, a phase Ib study combining first line afatinib with anti-EGF vaccination in EGFR-mutant metastatic NSCLC-Reference-Cited by-同舟云学术

The EPICAL trial, a phase Ib study combining first line afatinib with anti-EGF vaccination in EGFR-mutant metastatic NSCLC

Published:2022-02 Issue: Volume:164 Page:8-13
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Rodríguez-Abreu D.^ORCID,Cobo M.,García-Román S.,Viteri-Ramírez S.,Jordana-Ariza N.,García-Peláez B.,Reguart N.,Aguilar A.,Codony-Servat J.,Drozdowskyj A.,Molina-Vila M.A.,d'Hondt E.,Rosell R.^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference13 articles.

1. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial;Rosell;Lancet Oncol.,2012

2. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer;Soria;N. Engl. J. Med.,2018

3. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial;Park;Lancet Oncol.,2016

4. Randomized trial of afatinib plus cetuximab versus afatinib alone for first-line treatment of EGFR-mutant non-small-cell lung cancer: Final results from SWOG S1403;Goldberg;J. Clin. Oncol.,2020

5. Checkpoint inhibitors in metastatic EGFR-mutated non-small cell lung cancer-A meta-analysis;Lee;J. Thorac. Oncol.,2017

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Vaccine antibodies against a synthetic epidermal growth factor variant enhance the antitumor effects of inhibitors targeting the MAPK/ERK and PI3K/Akt pathways;Translational Oncology;2024-02

2. Immune Deprivation of Growth Factors as Cancer Therapy;Handbook of Cancer and Immunology;2023

3. Anti-EGF nanobodies enhance the antitumoral effect of osimertinib and overcome resistance in non-small cell lung cancer (NSCLC) cellular models;Medical Oncology;2022-09-07